Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study

Psoriatic Arthritis

A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK

Rheumatology (Oxford)

Gollins CE, Russell A, Smith T, Vivekanantham A, Brooke M, Coates LC, Gullick N, Helliwell P, McHugh N, Fahy C, Tillett W, SEQUENCE Study Group

doi: 10.1093/rheumatology/keaf570

Rheumatoid Arthritis

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Arthritis Care Res (Hoboken)

Xie F, Beukelman T, McCormick NP, Curtis JR

doi: 10.1002/acr.80010

Rheumatoid Arthritis

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Rheumatology (Oxford)

Molina-Collada J, Otero-Varela L, Vela P, Manrique S, Erausquin C, Campos C, Manero J, Calvo J, Expósito L, García González J, Ruiz Montesinos MD, Rabadán E, Varela AM, Vilamajo IR, Colazo Burlato M, Plasencia C, Sánchez-Alonso F, Castrejón I, BIOBADASER Project Collaborative Group

doi: 10.1093/rheumatology/keaf556

Rheumatoid Arthritis

Characteristics and long-term outcomes of patients with rheumatoid arthritis and concurrent calcium pyrophosphate deposition disease

Semin Arthritis Rheum

Schanzer N, England BR, Wysham KD, Riley TR 4th, Sauer B, Cannon GW, Mikuls TR, Baker JF

doi: 10.1016/j.semarthrit.2025.152902

Rheumatoid Arthritis

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

Rheumatology (Oxford)

Fujii T, Murata K, Nakabo S, Onishi A, Murakami K, Tanaka M, Morinobu A, Matsuda S

doi: 10.1093/rheumatology/keaf598

Rheumatoid Arthritis

The temporal trends and short- and long-term mortality of people with acute myocardial infarction and rheumatoid arthritis: a nationwide cohort study

Arthritis Care Res (Hoboken)

Butler M, Weight N, Rashid M, Bagur R, Parwani P, Hider S, Roddy E, Butler R, Mamas MA

doi: 10.1002/acr.70009

Rheumatoid Arthritis

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Ann Rheum Dis

Wientjes MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, Boers M, Hooijberg F, Rispens T, de Vries A, van Vollenhoven RF, Ramiro S, van Herwaarden N, van den Bemt BJF, den Broeder AA

doi: 10.1016/j.ard.2025.03.015

Rheumatoid Arthritis

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Ann Rheum Dis

Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A, Berger S, Rockwitz K, Krüger K, Schneider KM, Regierer AC, Strangfeld A

doi: 10.1016/j.ard.2025.05.014

Rheumatoid Arthritis

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Lancet Rheumatol

Cope AP, Jasenecova M, Vasconcelos JC, Qureshi S, van Schie KA, Filer A, Raza K, D'Agostino MA, McInnes IB, Siebert S, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Mankia K, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga TWJ, Toes REM, Georgiou E, Kelly J, Murphy C, Prevost AT, ALTO Study Investigators

doi: 10.1016/S2665-9913(25)00371-6

Related content

A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Characteristics and long-term outcomes of patients with rheumatoid arthritis and concurrent calcium pyrophosphate deposition disease

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

The temporal trends and short- and long-term mortality of people with acute myocardial infarction and rheumatoid arthritis: a nationwide cohort study

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial